The specific binding of [3H]EO-122, a radiolabeled class I antiarrhythmic drug to rat heart membranes.
[3H]EO-122, a radiolabeled class I antiarrhythmic drug, has been used to characterize a new specific binding system to rat heart membranes. The binding is saturable and competitive with unlabeled EO-122 and other antiarrhythmic drugs. In this system, [3H]EO-122 binds to two sites. Site A with an apparent Kd of 33.5 +/- 1.5 nM, Bmax of 1.05 +/- 0.15 pmol/mg protein and Hill coefficient nH = 4. Site B with an apparent Kd of 233 +/- 25 nM, Bmax equals 5.7 +/- 0.61 pmol/mg proteins and nH = 6. The binding to site B indicates that this site is pharmacologically relevant to known class IA antiarrhythmic drugs such as quinidine and procainamide. Lidocaine (class IB) does not interact with this site. Interpretation of the high Hill coefficient suggests that the binding of an antiarrhythmic drug to its pharmacologically relevant binding site exposes additional binding sites and/or modulates the affinity of adjacent binding sites.
Oppenheimer
E
E
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Meiri
H
H
Ori
Y
Y
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000378:metabolism*; D001665:Binding Sites; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism*; D008297:Male; D009928:Organ Specificity; D011812:Quinuclidines / Q000378:metabolism*; D051381:Rats; D015222:Sodium Channels / Q000378:metabolism*
D000889:Anti-Arrhythmia Agents; D011812:Quinuclidines; D015222:Sodium Channels; C026586:EO 122